---
title: "市場對諾華製藥的看法如何？"
description: "諾華製藥的空頭頭寸佔流通股的比例增加了 4.55%，目前有 438 萬股被賣空，佔可交易股份的 0.23%。交易者平均需要 1.88 天來平倉他們的空頭頭寸。空頭頭寸的增加可能表明市場情緒偏向看跌，而減少則可能暗示看漲情緒。與同行相比，諾華製藥的空頭頭寸較低，為 3.24%。這一趨勢並不一定預示着短期內股價會下跌"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/253257264.md"
published_at: "2025-08-15T18:07:08.000Z"
---

# 市場對諾華製藥的看法如何？

> 諾華製藥的空頭頭寸佔流通股的比例增加了 4.55%，目前有 438 萬股被賣空，佔可交易股份的 0.23%。交易者平均需要 1.88 天來平倉他們的空頭頭寸。空頭頭寸的增加可能表明市場情緒偏向看跌，而減少則可能暗示看漲情緒。與同行相比，諾華製藥的空頭頭寸較低，為 3.24%。這一趨勢並不一定預示着短期內股價會下跌

Novartis's NVS short percent of float has risen 4.55% since its last report. The company recently reported that it has 4.38 million shares sold short, which is 0.23% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.88 days to cover their ...

### Related Stocks

- [NVS.US - 諾華制藥](https://longbridge.com/zh-HK/quote/NVS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Novartis Vanrafia(R) Phase III data support slowing of kidney function decline in patients with IgA nephropathy | (MORE TO FOLLOW) Dow Jones Newswires February 13, 2026 01:15 ET (06:15 GMT) | [Link](https://longbridge.com/zh-HK/news/275856996.md) |
| Novartis reports final data of ALIGN trial in IgAN | Novartis has reported final data from the Phase III ALIGN trial, demonstrating that Vanrafia (atrasentan) significantly  | [Link](https://longbridge.com/zh-HK/news/276055699.md) |
| Short Interest in Schneider Electric SE (OTCMKTS:SBGSY) Drops By 16.8% | Schneider Electric SE (OTCMKTS:SBGSY) experienced a 16.8% decrease in short interest in January, with 197,858 shares sho | [Link](https://longbridge.com/zh-HK/news/276071356.md) |
| Nokia Senior Manager David Heard Sells 275,000 Shares | Nokia Corporation senior manager David Heard sold 275,000 shares on February 16, 2026, at a volume-weighted average pric | [Link](https://longbridge.com/zh-HK/news/276075199.md) |
| Assetmark Inc. Sells 82,501 Shares of Boston Scientific Corporation $BSX | Assetmark Inc. has reduced its stake in Boston Scientific Corporation (NYSE:BSX) by 41.6%, selling 82,501 shares in the  | [Link](https://longbridge.com/zh-HK/news/276044910.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。